Pulmonary Function and Survival 1 Year After Dupilumab Treatment of Acute Moderate to Severe Coronavirus Disease 2019: A Follow-up Study From a Phase 2a Trial.

"Potential conflicts of interest. All authors: No reported conflicts."

"Financial support. This work was supported by the Virginia Biosciences Health Research Corporation; PBM C19 Research, LLC of PBM Capital; the Henske Family Foundation; and the National Institutes of Health (grant numbers R01 AI124214 to W. A. P., T32 DK072922 and TL1 DK132771 to J. H., and UL1TR003015 and KL2TR003016 to J. M. S. and J. Z. M.). J. H. is an Integrated Translational Health Research Institute of Virginia (iTHRIV) Scholar. The iTHRIV Scholars Program is supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1TR003015 and KL2TR003016. J. E. A. was funded by the Medical Research Council UK (MR/V011235/1) and the Wellcome Trust (106898/A/15/Z). Financial support ."

"Notes: Acknowledgments. We thank the patients who consented to enroll in this study to help others with post-COVID-19 conditions; the staff at the University of Virginia (UVA) Post COVID clinic for their assistance with this follow-up study; and Amy Warren and Lori Elder for institutional review board (IRB) protocol preparation and Investigational New Drug (IND) preparation, submission, and maintenance. We also thank the Biorepository and Tissue Research Facility at UVA who collected, organized, and analyzed research samples.: Patient consent. Approval for the original phase 2a study was obtained through the US Food and Drug Administration IND application in April 2021. Approval through the IRB at UVA was obtained for the original phase 2a trial in June 2021. The trial is registered at ClinicalTrials.gov (NCT04920916). This follow-up study was approved by the UVA IRB in June 2022. Consent forms for follow-up visits were IRB-approved. Each participant was provided a verbal explanation of the study purposes, study procedures, potential risks of the study, and their rights as research participants, which was suited to the participant's comprehension. Participants had the opportunity to carefully review the written consent form, discuss with family or surrogates, and ask questions prior to signing.: Financial support. This work was supported by the Virginia Biosciences Health Research Corporation; PBM C19 Research, LLC of PBM Capital; the Henske Family Foundation; and the National Institutes of Health (grant numbers R01 AI124214 to W. A. P., T32 DK072922 and TL1 DK132771 to J. H., and UL1TR003015 and KL2TR003016 to J. M. S. and J. Z. M.). J. H. is an Integrated Translational Health Research Institute of Virginia (iTHRIV) Scholar. The iTHRIV Scholars Program is supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1TR003015 and KL2TR003016. J. E. A. was funded by the Medical Research Council UK (MR/V011235/1) and the Wellcome Trust (106898/A/15/Z)."